Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia

Journal of Clinical Psychiatry

Volumn 71, Issue 9, 2010, Pages 1131-1137

  Arakawa, Ryosuke ^a,b   Okumura, Masaki ^a,b   Ito, Hiroshi ^a   Takano, Akihiro ^a   Takahashi, Hidehiko ^a   Takano, Harumasa ^a   Maeda, Jun ^a   Okubo, Yoshiro ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DOPAMINE 2 RECEPTOR; HALOPERIDOL; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; OLANZAPINE; PROLACTIN; RISPERIDONE; SULPIRIDE; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; CARBON; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PYRROLIDINE DERIVATIVE; SALICYLAMIDE DERIVATIVE;

ADULT; ARTICLE; BRAIN CORTEX; CEREBELLUM; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; ISOTOPE LABELING; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; TEMPORAL CORTEX; BLOOD; CEREBELLUM CORTEX; CHEMICALLY INDUCED; COMPUTER GRAPHICS; DIAGNOSTIC USE; DOSE RESPONSE; DRUG EFFECTS; MATHEMATICAL COMPUTING; METABOLISM; MIDDLE AGED; SCINTISCANNING; STATISTICS; TEMPORAL LOBE; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CARBON RADIOISOTOPES; CEREBELLAR CORTEX; CEREBRAL CORTEX; COMPUTER GRAPHICS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; HYPERPROLACTINEMIA; MALE; MATHEMATICAL COMPUTING; MIDDLE AGED; PITUITARY GLAND; POSITRON-EMISSION TOMOGRAPHY; PROLACTIN; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RISPERIDONE; SALICYLAMIDES; SCHIZOPHRENIA; STATISTICS AS TOPIC; SULPIRIDE; TEMPORAL LOBE; YOUNG ADULT;

EID: 77957837936     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04307yel     Document Type: Article

References (50)

1. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14(3):163-173. PubMed doi:10.3109/ 10401230209147453
2. Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin. 2004;20(2):189-197. PubMed doi:10.185/030790312502865
3. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26-31. PubMed
4. Lieberman JA, Stroup TS, McEvoy JP, et al.Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. PubMed doi:10.1056/NEJMoa05168
5. Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci. 2001;251(3):141-146. PubMed doi:10.107/s0406017049
6. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761-767. PubMed (Pubitemid 40942424)
7. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491-1498. PubMed
8. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57-61. PubMed
9. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302(3):1129-1134. PubMed doi:10.124/jpet.102.035303
10. Jaber M, Robinson SW, Missale C, et al. Dopamine receptors and brain function. Neuropharmacology. 1996;35(11):1503-1519. PubMed doi:10.1016/S028- 3908(96)010-1
11. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-1631. PubMed
12. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. PubMed doi:10.176/api.ajp.157.4.514
13. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33(4):227-235. PubMed doi:10.1016/06-323(93)9028-O
14. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49(7):538-544. PubMed
15. 125I]epidepride. Brain Res. 1993;609(1-2):237-243. PubMed doi:10.1016/06-893(93)90878-Q
16. 2 dopamine receptors. J Nucl Med. 1995;36(7):1275-1281. PubMed
17. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry. 2002;59(1):25-30. PubMed doi:10.101/archpsyc.59.1.25
18. Takano A, Suhara T, Yasuno F, et al. The antipsychotic sultopride is overdosed - a PET study of drug-induced receptor occupancy in comparison with sulpiride. Int J Neuropsychopharmacol. 2006;9(5):539-545. PubMed doi:10.1017/S14614570506103
19. 11C]FLB 457. Int J Neuropsychopharmacol. 2003;6(4):361-370. PubMed doi:10.1017/S1461457030369
20. 2 dopamine receptors in the human brain. Neuroimage. 2001;13(3):531-539. PubMed doi:10.106/nimg.20.0717
21. 2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197(2): 229-235. PubMed doi:10.107/s0213-07-1029-z
22. 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46(3):170-188. PubMed doi:10.102/syn.10128
23. Bergström M, Muhr C, Lundberg PO, et al. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med. 1991;32(4):610-615. PubMed
24. 18F]fallypride. Neuropsychopharmacology. 2008;33(13):3111-3125. PubMed doi:10.1038/np.208.3
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
26. 2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl). 2001;154(1):112-114. PubMed doi:10.107/s02130643
27. 2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol. 1999;2(2):73-82. PubMed doi:10.1017/S1461457901431
28. Bickel U. How to measure drug transport across the blood-brain barrier. NeuroRx. 2005;2(1):15-26. PubMed doi:10.1602/neurorx.2.1.15 (Pubitemid 40128023)
29. Mannhold R, Cruciani G, Dross K, et al. Multivariate analysis of experimental and computational descriptors of molecular lipophilicity. J Comput Aided Mol Des. 1998;12(6):573-581. PubMed doi:10.1023/A:10806041562
30. Hansch C, Sammes P, Taylor J. Comprehensive Medicinal Chemistry. Oxford, UK: Pergamon Press; 1990.
31. 2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol. 1998;18(4):305-310. PubMed. doi:10.1097/04714-198080-010
32. 3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl). 2004;175(3):367-373. PubMed doi:10.107/s0213-04-1826-6
33. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38. PubMed
34. 11C]FLB 457 binding measured by PET. Synapse. 2001;41(2):87-95. PubMed doi:10.102/syn.1063
35. 1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: a PET study in conscious monkeys. Neuropsychopharmacology. 2005;30(12):2144-2153. PubMed doi:10.1038/sj.np.130745
36. 11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging. 2009;36(3):475-483. PubMed doi:10.107/s0259-08-0969-9
37. 2 dopamine receptor binding in the primate brain: a PET study. Synapse. 2000;38(2):138-143. PubMed doi:10.102/1098-2396(201)38:2〈138:AID- SYN4〉3.0.CO;2-7
38. 1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology. 2005;30(10):1861-1869. PubMed doi:10.1038/sj.np.130732
39. 11C]FLB 457. J Neurosci. 2005;25(10):2471-2477. PubMed doi:10.1523/JNEUROSCI.2097-04.205
40. Aalto S, Ihalainen J, Hirvonen J, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl). 2005;182(3):375-383. PubMed doi:10.107/s0213-05-092-6
41. 11C]FLB 457 PET. J Cereb Blood Flow Metab. 2007;27(2):369-377. PubMed doi:10.1038/sj.jcbfm.96039
42. 11C]fallypride. Synapse. 2009;63(6):447-461. PubMed doi:10.102/syn.20628
43. 2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol. 2009;12(5):667-675.
44. Mannens G, Meuldermans W, Snoeck E, et al. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994;114(4):566-572. PubMed doi:10.107/BF024986
45. El Ela AA, Härtter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004; 56(8):967-975. PubMed doi:10.121/02357043969 (Pubitemid 39140051)
46. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446(7137):749-757. PubMed doi:10.1038/nature05630
47. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71(2):163-169. PubMed doi:10.1016/S024-3205(02)01680-6
48. 3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res. 2006;85(1-3):232-244. PubMed doi:10.1016/j.schres.206.03.042
49. Tuppurainen H, Kuikka J, Viinamäki H, et al. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry. 2003;8(4):453-455. PubMed doi:10.1038/sj.mp.40134
50. 2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia. Life Sci. 2004;74(25):3115-3131. PubMed doi:10.1016/j.lfs.203.1.04